Linoleate-pazopanib conjugation as active pharmacological ingredient to abolish hepatocellular carcinoma growth

Linoleate-pazopanib conjugation as active pharmacological ingredient to abolish hepatocellular carcinoma growth

Small molecule compounds targeting multiple kinases involved in neoangiogenesis have shown survival benefits in patients with unresectable hepatocellular carcinoma (HCC). Nonetheless, despite the beneficial effects of multikinase inhibitors (MKIs), a lack of boosting adjuvant limits their objective...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Ke Wang, Pei-Yin Liao, Wei-Chun Chang, Cian-Ru Yang, Yu-Ting Su, Ping-Ching Wu, Yang-Chang Wu, Yao-Ching Hung, Najim Akhtar, Hsueh-Chou Lai, Wen-Lung Ma
Formáid: Alt
Teanga:English
Foilsithe / Cruthaithe: Frontiers Media S.A. 2024-01-01
Sraith:Frontiers in Pharmacology
Ábhair:
hepatocellular carcinoma
LDC
linoleate
pazopanib
LAPC
Rochtain ar líne:https://www.frontiersin.org/articles/10.3389/fphar.2023.1281067/full

Ar líne

https://www.frontiersin.org/articles/10.3389/fphar.2023.1281067/full

Míreanna comhchosúla